Compare Orchid Pharma with Piramal Enterprises - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

ORCHID PHARMA     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA PIRAMAL ENTERPRISES ORCHID PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x -116.9 -40.6 - View Chart
P/BV x 33.5 1.4 2,450.4% View Chart
Dividend Yield % 0.0 1.7 -  

Financials

 ORCHID PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    ORCHID PHARMA
Sep-13
PIRAMAL ENTERPRISES
Mar-19
ORCHID PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs1943,303 5.9%   
Low Rs351,797 1.9%   
Sales per share (Unadj.) Rs276.5716.5 38.6%  
Earnings per share (Unadj.) Rs-79.279.7 -99.4%  
Cash flow per share (Unadj.) Rs-43.5107.9 -40.3%  
Dividends per share (Unadj.) Rs028.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs53.91,477.5 3.7%  
Shares outstanding (eoy) m70.45184.45 38.2%   
Bonus / Rights / Conversions ESOPIS-  
Price / Sales ratio x0.43.6 11.6%   
Avg P/E ratio x-1.432.0 -4.5%  
P/CF ratio (eoy) x-2.623.6 -11.2%  
Price / Book Value ratio x2.11.7 123.0%  
Dividend payout %035.1 0.0%   
Avg Mkt Cap Rs m8,067470,292 1.7%   
No. of employees `0002.87.8 35.8%   
Total wages/salary Rs m2,52722,504 11.2%   
Avg. sales/employee Rs Th6,956.116,899.4 41.2%   
Avg. wages/employee Rs Th902.52,877.7 31.4%   
Avg. net profit/employee Rs Th-1,993.01,879.9 -106.0%   
INCOME DATA
Net Sales Rs m19,477132,153 14.7%  
Other income Rs m4073,128 13.0%   
Total revenues Rs m19,884135,281 14.7%   
Gross profit Rs m1,10366,290 1.7%  
Depreciation Rs m2,5195,202 48.4%   
Interest Rs m5,22744,097 11.9%   
Profit before tax Rs m-6,23620,119 -31.0%   
Minority Interest Rs m203,194 0.6%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1258,611 -1.5%   
Profit after tax Rs m-5,58014,701 -38.0%  
Gross profit margin %5.750.2 11.3%  
Effective tax rate %2.042.8 4.7%   
Net profit margin %-28.711.1 -257.5%  
BALANCE SHEET DATA
Current assets Rs m11,014122,742 9.0%   
Current liabilities Rs m32,060310,810 10.3%   
Net working cap to sales %-108.1-142.3 75.9%  
Current ratio x0.30.4 87.0%  
Inventory Days Days9523 411.3%  
Debtors Days Days3439 86.4%  
Net fixed assets Rs m29,440116,904 25.2%   
Share capital Rs m705369 191.0%   
"Free" reserves Rs m2,043272,161 0.8%   
Net worth Rs m3,800272,530 1.4%   
Long term debt Rs m9,018270,196 3.3%   
Total assets Rs m46,510856,261 5.4%  
Interest coverage x-0.21.5 -13.3%   
Debt to equity ratio x2.41.0 239.4%  
Sales to assets ratio x0.40.2 271.3%   
Return on assets %-0.86.9 -11.1%  
Return on equity %-146.95.4 -2,722.4%  
Return on capital %-3.712.4 -30.1%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51315,200 49.4%   
Fx outflow Rs m5,6494,889 115.5%   
Net fx Rs m1,86510,312 18.1%   
CASH FLOW
From Operations Rs m1,682-115,975 -1.5%  
From Investments Rs m-9,860-8,265 119.3%  
From Financial Activity Rs m6,644107,525 6.2%  
Net Cashflow Rs m-1,535-16,650 9.2%  

Share Holding

Indian Promoters % 32.3 52.9 61.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 4.0 115.0%  
FIIs % 3.3 26.6 12.4%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 16.5 335.2%  
Shareholders   84,811 93,274 90.9%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  FULFORD INDIA  ALKEM LABORATORIES  AJANTA PHARMA  

Compare ORCHID PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

4 Reasons Why Sensex Surged 848 Points Today(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY21); Net Profit Up 22.1% (Quarterly Result Update)

Aug 25, 2020 | Updated on Aug 25, 2020

For the quarter ended June 2020, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 22.1% YoY). Sales on the other hand came in at Rs 29 bn (down 16.2% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY20); Net Profit Up 11.7% (Quarterly Result Update)

Feb 5, 2020 | Updated on Feb 5, 2020

For the quarter ended December 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 11.7% YoY). Sales on the other hand came in at Rs 38 bn (up 9.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY20); Net Profit Up 16.5% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 16.5% YoY). Sales on the other hand came in at Rs 36 bn (up 14.6% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

More Views on News

Most Popular

Is Intraday Trading For You?(Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA SHARE PRICE


May 17, 2021 (Close)

TRACK ORCHID PHARMA

  • Track your investment in ORCHID PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ORCHID PHARMA 5-YR ANALYSIS

COMPARE ORCHID PHARMA WITH

MARKET STATS